ProCE Banner Activity

Is There Ever a Reason to Use Anticholinergics in Patients With Tardive Dyskinesia?

Clinical Thought
Anticholinergics improve parkinsonism but exacerbate TD, and VMAT2 inhibitors improve TD but do not treat parkinsonism and may worsen it. Jonathan Meyer, MD, explores this psychopharmacology topic and reflects on processes acting on different neurons.

Released: July 08, 2021

Expiration: July 07, 2022

No longer available for credit.

Share

Faculty

Jonathan M. Meyer

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant provided by

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Jonathan M. Meyer, MD, has disclosed that he has received consulting fees from Acadia, Alkermes, Intra-Cellular Therapeutics, and Neurocrine and fees for non-CME/CE services from Acadia, Alkermes, Intra-Cellular Therapeutics, Neurocrine, Noven, Otsuka, and Sunovion.